CRC Research Update — July 17, 2026
Today's colorectal cancer research highlights
Archive
A collection of 715 issues
Latest
Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer
Skip to content
The CRC Digest
Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer
Review outlines next-generation precision approaches for microsatellite-stable tumors, including antibody-drug conjugates, bispecific antibodies, DNA damage response targeting, and tumor microenvironment-directed therapies. (ESMO Open)
This content is informational only and does not constitute medical
DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC
Skip to content
The CRC Digest
DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC
Preclinical study investigated why dMMR/MSI colorectal cancers are intrinsically immunogenic and why some do not respond or develop resistance to immune checkpoint inhibitors. (Gastroenterology)
This content is informational only and does not
CRC Research Finding
Skip to content
The CRC Digest
◇ Review examines anti-VEGF plus checkpoint inhibitor combinations in GI cancers
A narrative review synthesizes preclinical and clinical data on combining anti-VEGF agents with immune checkpoint inhibitors across gastrointestinal cancers, including colorectal cancer, with emphasis on optimal sequencing strategies. (Discov Oncol)
This content is informational
CRC Research Update — July 16, 2026
Today's colorectal cancer research highlights
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
Skip to content
The CRC Digest
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84
RAS mutation linked to early progression in liver metastases conversion therapy
Skip to content
The CRC Digest
RAS mutation linked to early progression in liver metastases conversion therapy
Retrospective study of 194 patients with initially unresectable, pMMR colorectal liver metastases found that RAS mutation status was associated with early progression or recurrence after conversion therapy. (Front Surg)
This content is informational
Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC
Skip to content
The CRC Digest
Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC
Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol)
This content is informational only and does not
New tool prioritizes colonoscopy for highest-risk patients
Skip to content
The CRC Digest
New tool prioritizes colonoscopy for highest-risk patients
Decision-tree model using fecal hemoglobin and clinical data helps stratify CRC risk among those with positive fecal immunochemical tests, addressing colonoscopy capacity constraints. (Dig Endosc)
This content is informational only and does not constitute medical advice.
Always
Missed screening opportunities lead to emergency diagnosis and worse outcomes
Skip to content
The CRC Digest
Missed screening opportunities lead to emergency diagnosis and worse outcomes
SEER-Medicare analysis of older adults found that many CRC cases are diagnosed during emergency presentation, which are linked to worse outcomes compared to screening-detected cases. (J Surg Oncol)
This content is informational only and